首页> 外国专利> IMMUNOTHERAPY USING ALLO-NKT CELLS, CELLS FOR IMMUNOTHERAPY IN WHICH alpha CHAIN OF T-CELL RECEPTOR (TCR) GENE HAS BEEN REARRANGED TO UNIFORM V alpha-J alpha , AND BANKING OF NKT CELLS DERIVED FROM SAID CELLS

IMMUNOTHERAPY USING ALLO-NKT CELLS, CELLS FOR IMMUNOTHERAPY IN WHICH alpha CHAIN OF T-CELL RECEPTOR (TCR) GENE HAS BEEN REARRANGED TO UNIFORM V alpha-J alpha , AND BANKING OF NKT CELLS DERIVED FROM SAID CELLS

机译:使用同种异体-NKT细胞进行免疫治疗,将T细胞受体(TCR)基因的alpha链重新排列成均匀的V alpha-J alpha的免疫治疗细胞,以及将上述细胞衍生的NKT细胞进行包装

摘要

The present invention provides an agent for an immunocyte therapy, comprising an NKT cell obtained by differentiating in vitro a cell having the ±-chain region of the T cell receptor gene rearranged to uniform V±-J± in an NKT cell receptor-specific way, wherein an administration subject is an allogenic individual having MHC gene loci including at least one locus having a genotype different from that of the NKT cell. In addition, the present invention provides a bank of a human cell or an NKT cell derived from said cell, wherein the ±-chain region of a T cell receptor (TCR) gene has been rearranged to uniform V±-J±. The agent and cell bank of the present invention are useful for the prophylaxis and/or treatment of cancer, infection, an allergic disease or an autoimmune disease.
机译:本发明提供了一种免疫细胞治疗剂,其包括NKT细胞,该NKT细胞是通过体外分化具有以NKT细胞受体特异性方式重新排列成均匀的V±-J±的T细胞受体基因的±链区的细胞而获得的。 ,其中施用对象是具有MHC基因位点的同种异体个体,其包括至少一个基因型与NKT细胞不同的基因座。另外,本发明提供了人细胞库或由所述细胞衍生的NKT细胞库,其中T细胞受体(TCR)基因的±链区已被重新排列为均匀的V±J±。本发明的试剂和细胞库可用于预防和/或治疗癌症,感染,变应性疾病或自身免疫性疾病。

著录项

  • 公开/公告号EP2647384B1

    专利类型

  • 公开/公告日2018-05-23

    原文格式PDF

  • 申请/专利权人 RIKEN;

    申请/专利号EP20110844377

  • 申请日2011-12-02

  • 分类号A61K35/17;A61K31/7028;A61P31;A61P35;A61P37/06;A61P37/08;A61K45/06;C07K14/725;C12N5/0783;

  • 国家 EP

  • 入库时间 2022-08-21 13:19:07

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号